Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 1 of 1 entries
Sorted by: Best Match Show Resources per page
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.

Journal for immunotherapy of cancer

Ross-Macdonald P, Walsh AM, Chasalow SD, Ammar R, Papillon-Cavanagh S, Szabo PM, Choueiri TK, Sznol M, Wind-Rotolo M.
PMID: 33658305
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001506.

BACKGROUND: Nivolumab is an immune checkpoint inhibitor targeting the programmed death-1 receptor that improves survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). In contrast to other tumor types that respond to immunotherapy, factors such...

Cite
Ross-Macdonald P, Walsh AM, Chasalow SD, et al. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. J Immunother Cancer. 2021;9(3)doi: 10.1136/jitc-2020-001506.
Ross-Macdonald, P., Walsh, A. M., Chasalow, S. D., Ammar, R., Papillon-Cavanagh, S., Szabo, P. M., Choueiri, T. K., Sznol, M., & Wind-Rotolo, M. (2021). Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. Journal for immunotherapy of cancer, 9(3), . https://doi.org/10.1136/jitc-2020-001506
Ross-Macdonald, Petra, et al. "Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC." Journal for immunotherapy of cancer vol. 9,3 (2021). doi: https://doi.org/10.1136/jitc-2020-001506
Ross-Macdonald P, Walsh AM, Chasalow SD, Ammar R, Papillon-Cavanagh S, Szabo PM, Choueiri TK, Sznol M, Wind-Rotolo M. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001506. PMID: 33658305; PMCID: PMC7931766.
Copy Download .nbib Format: NLM
Showing 1 to 1 of 1 entries